- Home
- MYGN vs GAU Comparison
MYGN vs GAU Comparison
Compare MYGN & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYGN | GAU |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 731.5M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYGN | GAU |
|---|---|---|
| Price | $7.17 | $2.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $12.58 | $3.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.9M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $825,300,000.00 | $352,642,000.00 |
| Revenue This Year | $0.10 | $82.50 |
| Revenue Next Year | $5.28 | $57.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.21 | ★ 111.43 |
| 52 Week Low | $3.76 | $1.00 |
| 52 Week High | $16.63 | $3.12 |
Technical Indicators
Market Signals| Indicator | MYGN | GAU |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 53.28 |
| Support Level | $6.93 | $2.30 |
| Resistance Level | $7.38 | $2.46 |
| Average True Range (ATR) | 0.39 | 0.13 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 39.88 | 78.10 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.